Actively Recruiting
Video Education With Result Dependent Disclosure to Improve Genetic Testing Access for Hereditary Cancer Risk
Led by Dana-Farber Cancer Institute · Updated on 2026-05-22
1020
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
Sponsors
D
Dana-Farber Cancer Institute
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating strategies to improve the accessibility of the Video Education with Result Dependent Disclosure (VERDI) model, which is used as a pre-genetic testing education alternative for people at risk of hereditary cancers including breast, ovarian, pancreatic, prostate, colorectal, renal cancers, melanoma, and sarcoma. The study aims to better serve a diverse patient population by refining and testing this educational approach compared to standard genetic counseling. The study has two parts. The first part involves a qualitative assessment where about 20 participants watch an 8-minute educational video about genetic testing for inherited cancer risk and then complete a short interview by video or phone. The second part is a randomized controlled trial with 1000 participants comparing the VERDI video education model to standard genetic counseling. Both interventions are behavioral in nature, focusing on education about genetic testing. Participants will be involved by watching the educational video and/or receiving genetic counseling, followed by interviews or assessments. Researchers will measure outcomes such as the acceptability of the video education through qualitative interviews conducted within three weeks. The study includes informed consent, and participants must be able to understand English or Spanish. The total duration and follow-up details vary by study part.
CONDITIONS
Brief Title
Video Education With Result Dependent dIsclosure
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Current or prior diagnosis of breast cancer, ovarian cancer, pancreatic cancer, prostate cancer, colorectal cancer, renal cancer, melanoma, or sarcoma
- Ability to understand spoken or written English or Spanish in a healthcare context
- Ability and willingness to sign a written informed consent document
- Black or Latinx individuals (for qualitative assessment study only)
You will not qualify if you...
- Prior cancer genetic testing
- Prior germline genetic testing
- Active hematologic malignancy such as chronic lymphocytic leukemia
- Currently pregnant
- Currently incarcerated
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote)
Duration - Single session
Participants watch an 8-minute educational video about genetic testing for inherited cancer risk followed by either standard genetic counseling or the VERDI model intervention.
1 visit (in-person or remote)
Trial Site Locations
Total: 1 location
1
Dana Farber Cancer Institute
Boston, Massachusetts, United States, 02115
Actively Recruiting
Research Team
H
Huma Q. Rana, MD. MPH
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here